The deal isn’t done, but would be Merck’s biggest oncology buy.
ApexOnco Front Page
Recent articles
10 February 2025
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
10 February 2025
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
6 February 2025
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
6 February 2025
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
5 February 2025
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
4 February 2025
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
4 February 2025
Felmetatug vedotin’s exit could be bad news for Mersana.